NTI164
Phase 3Small molecule
NTI164 is one of 59 small molecule programs targeting Rett syndrome. It is currently in Phase 3.
2
Indications
6
Total Trials
5
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
160 competitors in Autism Spectrum Disorder
#DrugCompanyPhaseTrials
1Vraylar
AbbViePhase 3
Elavil
AstraZenecaPhase 3
Bumex
VValidus Pharmaceuticals
Phase 3
Rexulti
OtsukaPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Glucophage
EMD SeronoPhase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Karxt
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autism Spectrum Disorder2 trials
Rett syndrome2 trials
Cannabis1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NTI164. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFenix Innovation Group